Meet the OBR Editorial Board

Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.

View all Editorial Board Member Commentary

Browse Editors by Section

member-photo

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Comments

Update on PALLAS, an International Academic Breast Cancer Study Evaluating Adjuvant Palbociclib Second Interim Analysis of Adjuvant

quotesThe interim analysis of the very large PALLAS trial testing the addition of 2 years of palbociclib t…quotes

member-photo

Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System

Comments

UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug

quotesThe FDA has approved a new formulation of Mitomycin C (MMC) in hydrogel (4 mg/ml) solution for insti…quotes

member-photo

Ted Okon

Executive Director
Community Oncology Alliance

Comments

PBM Middlemen Continue to Dodge Responsibility for Patient Suffering and Rising Drug Prices

quotesPBMs are getting more brazen in how they delay and deny cancer patients their oral drugs. Anyone in …quotes

member-photo

William McGivney, PhD

National Health Policy Expert

Comments

ICER Presents Alternative Pricing Models for Remdesivir as a Treatment for COVID-19

quotesICER steps in to take advantage of “informing the public debate” (I did not know we were there y…quotes

member-photo

Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine

Comments

FDA Approves Olaparib For HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

quotesPAPR inhibitor approval means that we will need to genotype all advanced prostate cancer patients. …quotes

member-photo

Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine

Comments

FDA Approves Olaparib For HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

quotesPAPR inhibitor approval means that we will need to genotype all advanced prostate cancer patients. …quotes

member-photo

Dean Gesme, MD

FACP FACPE FASCO
President, Minnesota Oncology

Comments

Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer

quotesDisappointing that adding palbociclib to Standard adjuvant aromatase inhibitor therapy for Stage II …quotes

member-photo

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Comments

Update on PALLAS, an International Academic Breast Cancer Study Evaluating Adjuvant Palbociclib Second Interim Analysis of Adjuvant

quotesThe interim analysis of the very large PALLAS trial testing the addition of 2 years of palbociclib t…quotes

member-photo

H. Jack West, MD

Associate Clinical Professor, Medical Oncology
Executive Director, Employer Services
City of Hope Comprehensive Cancer Center
Duarte, CA

Comments

Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

quotesThis is a regimen that hasn't demonstrated a survival benefit. I would expect that it should achieve…quotes

member-photo

Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System

Comments

UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug

quotesThe FDA has approved a new formulation of Mitomycin C (MMC) in hydrogel (4 mg/ml) solution for insti…quotes

member-photo

Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics

Professor and Chair, Department of Radiation Oncology

Interim Director, Samuel Oschin Comprehensive Cancer Institute

Cedars-Sinai Medical Center

Comments

Radiotherapy Can Be Used In Hard-to-treat Bladder Cancer

quotesRadiotherapy as primary treatment (along with TUR and chemotherapy) is having a bit of a renaissance…quotes

member-photo

Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology
Department of Medicine,Cedars-Sinai Medical Center
Associate Director for Academic Program Development
Samuel Oschin Comprehensive Cancer Institute
Professor of Medicine and Urology, Emeritus
David Geffen School of Medicine at UCLA

Comments

CT Scans Can Reduce Lung Cancer Deaths, Study Finds

quotesThis long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …quotes

member-photo

Stephen M. Schleicher, M.D., MBA

Community Oncology,
Medical Oncologist,
OneOncology

No comments to show!

member-photo

Ted Okon

Executive Director
Community Oncology Alliance

Comments

PBM Middlemen Continue to Dodge Responsibility for Patient Suffering and Rising Drug Prices

quotesPBMs are getting more brazen in how they delay and deny cancer patients their oral drugs. Anyone in …quotes

member-photo

Thomas Marsland, MD

Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors

Comments

Conquer Cancer, the ASCO Foundation, Grants More Than $8 Million to Cancer Research

quotesAs a Conquer Cancer board member I am extremely proud of our support for cutting edge research. I am…quotes

member-photo

William McGivney, PhD

National Health Policy Expert

Comments

ICER Presents Alternative Pricing Models for Remdesivir as a Treatment for COVID-19

quotesICER steps in to take advantage of “informing the public debate” (I did not know we were there y…quotes

member-photo

H. Jack West, MD

Associate Clinical Professor, Medical Oncology
Executive Director, Employer Services
City of Hope Comprehensive Cancer Center
Duarte, CA

Comments

Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

quotesThis is a regimen that hasn't demonstrated a survival benefit. I would expect that it should achieve…quotes

member-photo

Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology
Department of Medicine,Cedars-Sinai Medical Center
Associate Director for Academic Program Development
Samuel Oschin Comprehensive Cancer Institute
Professor of Medicine and Urology, Emeritus
David Geffen School of Medicine at UCLA

Comments

CT Scans Can Reduce Lung Cancer Deaths, Study Finds

quotesThis long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …quotes

member-photo

Dean Gesme, MD

FACP FACPE FASCO
President, Minnesota Oncology

Comments

Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer

quotesDisappointing that adding palbociclib to Standard adjuvant aromatase inhibitor therapy for Stage II …quotes

member-photo

Thomas Marsland, MD

Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors

Comments

Conquer Cancer, the ASCO Foundation, Grants More Than $8 Million to Cancer Research

quotesAs a Conquer Cancer board member I am extremely proud of our support for cutting edge research. I am…quotes

member-photo

Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics

Professor and Chair, Department of Radiation Oncology

Interim Director, Samuel Oschin Comprehensive Cancer Institute

Cedars-Sinai Medical Center

Comments

Radiotherapy Can Be Used In Hard-to-treat Bladder Cancer

quotesRadiotherapy as primary treatment (along with TUR and chemotherapy) is having a bit of a renaissance…quotes